🔴 Cerenome is trading 6.9% down in pre-market with no clear company-specific catalyst identified

Cerenome is trading at $1.21, down 6.92%, with no clear company-specific announcement explaining the pre-market decline. - The latest major update was October 29: Cerenome completed Phase 2 ReSPECT-GBM enrollment and said topline data are expected in mid-2027. - Shares had already fallen 23.98% on November 3; major U.S. indices are indicated higher, so broad-market weakness does not explain this move. - No trading volume or confirmed catalyst is available for the pre-market move.